Rein Therapeutics, Inc. · NASDAQ:RNTX
Voss Capital, LP reported a 5.60% stake in Rein Therapeutics, Inc. (Schedule 13G)
Event May 8, 2025 · Filed May 14, 2025
Voss Capital, LP reported a 5.60% stake in Rein Therapeutics, Inc., 1,277,856 shares, as a passive investor on May 8, 2025. Filed May 14, 2025 (Schedule 13G).
- Stake
- 5.60%
- Shares
- 1,277,856
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 5 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Voss Value Master Fund, LP | 2.50% | 583,206 |
| Voss Value-Oriented Special Situations Fund, LP | 1.40% | 316,768 |
| Voss Advisors GP, LLC | 3.90% | 899,974 |
| Voss Capital, LP | 5.60% | 1,277,856 |
| Cocke Travis W. | 5.60% | 1,277,856 |
Source
Related
- Rein Therapeutics, Inc.
- Voss Capital, LP
- Rein Therapeutics, Inc. shareholders
- Schedule 13G/A · Voss Capital, LP · Jul 14, 2026
- Schedule 13G/A · Voss Capital, LP · Feb 13, 2026
- Schedule 13G/A · Voss Capital, LP · Sep 26, 2025
- Schedule 13G/A · Lynwood Capital Management Inc. · Aug 14, 2026
- Schedule 13G · ADAR1 Capital Management, LLC · Aug 14, 2026
- Schedule 13G/A · Laurence W. Lytton · Aug 13, 2026
- Form 4 · Von Rickenbach Josef H · May 28, 2026
- Form 4 · Windsor James Brian · May 13, 2026